Elevated genetic risk for pulse pressure is linked to a higher likelihood of dementia-related mortality among older adults.

The Food and Drug Administration (FDA) has granted Fast Track designation to remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer disease psychosis (ADP).

Blood-based biomarkers can help improve accuracy when diagnosing Alzheimer disease and related cognitive impairment or dementia.

Consumers are being warned by the CDC to avoid shredded iceberg lettuce from certain restaurants and providers in a handful of states.

There is an association between higher p-tau217 levels and increased risk for adverse cognitive outcomes among older adults.

Experts push for improving cancer prevention initiatives as cancer incidence burden is predicted to reach more than 34 million by 2050.

The FDA accepts Dyne’s BLA with Priority Review for zeleciment rostudirsen in exon 51 skipping DMD, setting a PDUFA target action date of January 21, 2027.

Use of GLP-1 RAs is associated with a higher risk for ischemic optic neuropathy compared with SGLT2is and DPP4is.

The FDA has approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, for adult hypercholesterolemia and HeFH.

Recent wildfires contribute to a significant reduction in air quality across the Midwestern and Northeastern parts of Canada and the US.

Postmenopausal women with a history of migraine may have an increased risk for ischemic stroke, according to recent study findings.

The FDA has granted Fast Track designation to invobenitug, an investigational anti-cDPP3 monoclonal antibody designed to restore RAAS balance in cardiogenic shock.